10-Q: HealthLynked Corp. Reports Q1 2025 Results: Revenue Declines Amid Cost-Cutting Efforts
Quarterly Report
HealthLynked Corp.'s Q1 2025 revenue decreased by 23% year-over-year, although the net loss was reduced due to cost-cutting measures.
Summary
- HealthLynked Corp. reported a net loss of $1,050,939 for the three months ended March 31, 2025, compared to a net loss of $1,387,718 for the same period in 2024.
- Total revenue decreased by 23% to $774,208, primarily due to a decline in patient service revenue and product revenue.
- Patient service revenue decreased by 22% to $752,015, mainly due to the discontinuation of the Naples Women's Center (NWC) and reduced revenue at Naples Center for Functional Medicine (NCFM).
- Product revenue decreased by 62% to $12,609 due to decreased marketing efforts and demand for products at MedOffice Direct (MOD).
- Operating expenses decreased by 37% to $629,415, primarily due to lower salaried overhead, stock-based compensation, and consulting costs.
- The company's cash balance as of March 31, 2025, was $22,270, with a working capital deficit of $4,032,140 and an accumulated deficit of $49,215,554.
- The company has substantial doubt about its ability to continue as a going concern through May 15, 2026, without raising additional capital.
- The company issued new convertible notes payable to its CEO, Dr. Michael Dent, for $175,000 and refinanced existing notes with an aggregate principal of $1,216,500.
- The company also refinanced undocumented advances received in the third and fourth quarters of 2024 into a convertible note payable with a principal amount of $420,000.
- The company issued notes payable to third parties for net cash proceeds of $305,000 and made repayments on third-party notes of $111,418.
Sentiment
Score: 3
Explanation: The document indicates a challenging financial situation for HealthLynked, with declining revenue, a significant accumulated deficit, and substantial doubt about its ability to continue as a going concern without raising additional capital. While cost-cutting measures have helped reduce the net loss, the overall outlook is negative.
Positives
- Net loss decreased by 24% due to cost reduction efforts.
- Practice salaries and benefits decreased by 31% due to focused cost reduction efforts.
- Other practice operating costs decreased by 35% due to focused cost reduction efforts.
- Selling, general and administrative costs decreased by 37% due to lower overhead and stock-based compensation.
Negatives
- Total revenue decreased by 23% due to a decline in patient service revenue and product revenue.
- Patient service revenue decreased by 22% due to the discontinuation of NWC and reduced revenue at NCFM.
- Product revenue decreased by 62% due to decreased marketing efforts and demand for products at MOD.
- The company has substantial doubt about its ability to continue as a going concern without raising additional capital.
- The company's cash balance as of March 31, 2025, was $22,270, with a working capital deficit of $4,032,140 and an accumulated deficit of $49,215,554.
Risks
- The company's ability to continue as a going concern is dependent on raising additional capital.
- The company faces uncertainty related to product development and generating revenue from its Digital Healthcare Division.
- The company is dependent on outside sources of capital.
- The company has a significant accumulated deficit of $49,215,554.
- The company relies on a single supplier for the fulfillment of substantially all of its product sales made through MOD.
Future Outlook
The company plans to profitably operate its Health Services business and continue to invest in its Digital Healthcare business, including the HealthLynked Network. The company intends to raise additional capital to fund its ongoing plan of operation.
Industry Context
The company operates in the healthcare services, digital healthcare, and medical distribution industries, which are subject to evolving market dynamics, regulatory changes, and technological advancements. The decline in revenue and the need for additional capital reflect the challenges faced by smaller companies in these competitive sectors.
Comparison to Industry Standards
- It is difficult to compare HealthLynked's results directly to industry standards due to its unique combination of health services, digital healthcare, and medical distribution.
- However, the decline in revenue and the need for additional capital are common challenges for small companies in the competitive healthcare and technology sectors.
- Comparable companies in the digital healthcare space, such as Teladoc Health and Amwell, have also experienced fluctuating revenue growth and profitability challenges.
- In the medical distribution sector, companies like McKesson and Cardinal Health operate on a much larger scale and have different financial profiles.
Related Party Transactions
- The company issued new convertible notes payable to its CEO, Dr. Michael Dent, for $175,000.
- The company refinanced existing notes with an aggregate principal of $1,216,500 with Dr. Michael Dent.
- The company refinanced undocumented advances received in third and fourth quarter of 2024 into a convertible note payable with a principal amount of $420,000 with Dr. Michael Dent.
Stakeholder Impact
- Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
- Employees may be affected by cost-cutting measures and the uncertainty surrounding the company's ability to continue as a going concern.
- Customers may experience changes in service offerings as the company focuses on profitability and cost reduction.
- Suppliers and creditors face increased risk due to the company's financial challenges and dependence on additional funding.
Next Steps
- The company plans to raise additional capital to fund its ongoing plan of operation.
- The company is marketing the HealthLynked Network by targeting large health systems, hospitals and universities.
- The company also intends to utilize physician telesales through the use of telesales representatives whom they will hire as access to capital allows.
Key Dates
| Date | Description |
|---|---|
| 2014-08-04 | HealthLynked Corp. was incorporated in the State of Nevada. |
| 2014-09-02 | The Company filed Amended and Restated Articles of Incorporation with the Secretary of State of Nevada. |
| 2016-01-01 | The Company adopted the 2016 Equity Incentive Plan (the 2016 EIP). |
| 2018-02-05 | The Company filed an Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of Nevada to increase the number of authorized shares of common stock to 500,000,000 shares. |
| 2020-06-30 | During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. |
| 2020-07-31 | During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. |
| 2020-08-31 | During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. |
| 2022-07-05 | The Company entered into a Standby Equity Purchase Agreement (the SEPA) with YA II PN, Ltd. (Yorkville). |
| 2023-01-17 | The Company entered into the AHP Merger Agreement, pursuant to which PBACO Holding, LLC (the Buyer) agreed to buy, and the Company agreed to sell, AHP (the AHP Sale). |
| 2023-03-14 | The Company issued a promissory note payable to a trust controlled by Dr. Dent with a stated principal amount of $112,510 and prepaid interest of $13,501 for total scheduled repayments of $126,011 (the March 2023 Dent Note). |
| 2023-06-26 | The Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $25,000 (the June 2023 Dent Note II). |
| 2023-08-08 | The Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the August 2023 Note). |
| 2023-11-03 | The Company issued to Yorkville a note payable (the November 2023 Note) with an initial principal amount equal to $350,000 at a purchase price equal to the principal amount of the November 2023 Note less any original issue discounts and fees. |
| 2023-12-01 | The Company issued an unsecured promissory note to a trust controlled by Dr. Dent a promissory note with a face value of $150,000 (the December 2023 Dent Note). |
| 2023-12-12 | The Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the December 2023 Note I). |
| 2023-12-13 | The Company issued to Yorkville a convertible note (the December 2023 Note II) with an initial principal amount equal to $175,000 at a purchase price equal to the principal amount of the December 2023 Note II less any original issue discounts and fees. |
| 2024-03-27 | The Company issued to a trust controlled by Dr. Michael Dent three separate notes payable as follows: (1) a note payable with a principal of $350,000, an interest rate of 12% per annum, and a maturity date of June 27, 2024 (the March 2024 Dent Note I), (2) a note payable with a principal of $150,000, an interest rate of 12% per annum, and an original maturity date of August 24, 2024 (the March 2024 Dent Note II), and (3) a note payable with a principal of $166,500, an interest rate of 12% per annum, and a maturity date of August 28, 2024 (the March 2024 Dent Note III, and collectively, the March 2024 Dent Notes). |
| 2024-04-10 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of October 10, 2024 (the April 2024 Dent Note I). |
| 2024-04-18 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $50,000, an interest rate of 12% per annum, and a maturity date of October 18, 2024 (the April 2024 Dent Note II). |
| 2024-04-22 | The Company issued a promissory note payable (the April 2024 Note) to an investor with a stated principal amount of $161,000 and prepaid interest of $19,320 for total repayments of $180,320. |
| 2024-06-03 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $1,000,000, an interest rate of 12% per annum, and a maturity date of June 3, 2025 (the June 2024 Dent Note). |
| 2024-07-30 | The Companys wholly owned subsidiary, HLYK Florida LLC, which owns NCFM, issued a promissory note payable to an investor with total principal repayments of $223,649 (the July 2024 Note). |
| 2024-09-19 | The Company issued to a trust controlled by Dr. Michael Dent ten separate senior secured convertible promissory note in the aggregate principal amount of $900,000, each with an interest rate of 12% per annum and maturity dates between January 1, 2025 and March 10, 2025 (the September 2024 Notes). |
| 2024-12-04 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $25,000, an interest rate of 12% per annum, and a maturity date of May 4, 2025 (the December 2024 Dent Note I). |
| 2024-12-17 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $70,000, an interest rate of 12% per annum, and a maturity date of June 17, 2025 (the December 2024 Dent Note II). |
| 2025-01-16 | The Company issued a promissory note payable (the January 2025 Note I) to an investor with a stated principal amount of $150,650 and prepaid interest of $18,078 for total repayments of $168,278. |
| 2025-01-24 | The Company issued a promissory note payable (the January 2025 Note II) to an investor with a stated principal amount of $98,900 and prepaid interest of $13,846 for total repayments of $112,746. |
| 2025-02-14 | The Company issued a promissory note payable (the February 2025 Note) to an investor with a stated principal amount of $121,900 and prepaid interest of $13,846 for total repayments of $14,628. |
| 2025-03-04 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $50,000, an interest rate of 12% per annum, and a maturity date of September 4, 2025. |
| 2025-03-12 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $60,000, an interest rate of 12% per annum, and a maturity date of September 12, 2025. |
| 2025-03-20 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $420,000, an interest rate of 12% per annum, and a maturity date of September 20, 2025. |
| 2025-03-27 | The Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $65,000, an interest rate of 12% per annum, and a maturity date of September 27, 2025. |
| 2025-05-15 | Date of filing of this Quarterly Report on Form 10-Q. |
Keywords
HealthLynked, Financial Results, Quarterly Report, Revenue, Net Loss, Cost Reduction, Going Concern, Convertible Notes, Healthcare, Digital Healthcare, Medical Distribution
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.